CPC
HRTX icon

Congress Park Capital’s Heron Therapeutics HRTX Stock Holding History

Congress Park Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300
Closed -$6K – 132
2020
Q4 		$6K Buy
+300
New +$5.21K ﹤0.01% 113
2020
Q2 		– Sell
-200
Closed -$2K – 94
2020
Q1 		$2K Buy
200
+100
+100% +$1.88K ﹤0.01% 87
2019
Q4 		$2K Buy
+100
New +$2.21K ﹤0.01% 97

Other funds holding HRTX

New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
AR
Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
SC
Searle & Co Greenwich, Connecticut $445M AUM 41.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Congress Park Capital's HRTX Position: Q2 2026 in Review

Congress Park Capital reduced its Heron Therapeutics (HRTX) stake by 50% in Q2 2026, selling an estimated $1.62M and leaving 2,016,447 shares worth $861K. The position accounts for 0.23% of the portfolio, ranked #70.

Congress Park Capital first reported a position in HRTX in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.52M in Q2 2024. 37 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Congress Park Capital held 2,016,447 shares of Heron Therapeutics worth $861K as of Q2 2026.
  • Congress Park Capital sold 2,016,290 Heron Therapeutics shares in Q2 2026, an estimated $1.62M.
  • Heron Therapeutics made up 0.23% of Congress Park Capital's portfolio in Q2 2026, its #70 holding.
  • Congress Park Capital first reported a position in Heron Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • Congress Park Capital's Heron Therapeutics position peaked at $5.52M in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.